Salix Pharmaceuticals (SLXP +7.1%) spikes higher on volume 3X normal trading activity after...

|About: Salix Pharmaceuticals, Ltd. (SLXP)|By:, SA News Editor

Salix Pharmaceuticals (SLXP +7.1%) spikes higher on volume 3X normal trading activity after Auriga upgrades it to a Buy rating with a $54 price target. Analysts call the firm's 2012 guidance conservative and indicate that they see a high likelihood that Salix will outperform.